MPI test to give old chemotherapy a new lease on life
The Danish company Medical Prognosis Institute has developed a biomarker test that should revitalize a common chemotherapy drug against breast cancer. CEO Peter Buhl Jensen calls it ”the biomarker of the future.”
BY MARTIN HAVTORN PETERSEN
The Danish diagnostics company Medical Prognosis Institute (MPI) has presented promising results for a new type of biomarker test, able to predict the efficacy of the chemotherapy epirubicin, one the of most used drugs in breast cancer treatment.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Oncology Venture wins CE marking for diagnostic tool
For abonnenter
